Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.
Ronald B VenderCharles W LyndePublished in: Journal of cutaneous medicine and surgery (2022)
CZP was effective and well tolerated in this cohort of patients with moderate-to-severe PsO in a real-world setting.